HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
ACE-031HPLC ≥ 99%MS confirmed1mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | ACE-031 |
|---|---|
| CAS number | 1169766-01-1 |
| Molecular weight | ≈77.24 kDa (calculated ActRIIB-Fc homodimer; glycosylated native runs ~90–100 kDa apparent) |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 1mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized ACE-031 at -20°C, protected from light and moisture. After reconstitution, keep at 2-8°C for near-term research use or aliquot and freeze at -20°C to -80°C to minimize freeze-thaw cycles. Follow lot-specific handling stated on the COA. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About ACE-031.
ACE-031 is a recombinant Fc-fusion protein comprising the extracellular domain of the activin type IIB receptor (ActRIIB / ACVR2B) linked to a human IgG1 Fc region, assembled as a disulfide-linked homodimer. In research models it functions as a soluble "ligand trap," sequestering TGF-β-superfamily ligands such as myostatin (GDF-8), activin A, and GDF-11 to block their signaling through native ActRIIB.
Documentation
Batch documentation support for ACE-031 lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the ACE-031 reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
ACE-031 — frequently asked by B2B buyers.
Is ACE-031 a peptide or a recombinant protein?
ACE-031 (ramatercept) is a recombinant Fc-fusion protein of roughly 77 kDa (a glycosylated ActRIIB-Fc homodimer), not a short synthetic peptide. It is produced in a mammalian expression system and handled as a biologic; lot-specific identity and mass are documented on the COA.
What documentation ships with each lot?
Each lot is supplied with a Certificate of Analysis covering identity (mass spec), purity (HPLC and SDS-PAGE), and standard protein-release checks. Endotoxin, appearance, and reconstitution notes can be added on request, and analytical traces are available under RFQ/NDA for OEM buyers.
What are the vial size and MOQ, and do you support private-label/OEM orders?
Catalog format is 1 mg per vial with a minimum order of 50 kits (500 vials). Bulk quantities, custom fill volumes, and private-label/OEM packaging (custom vials, labels, and kit configurations) are available on request with volume-based pricing.
Is ACE-031 approved for therapeutic or consumer use?
No. ACE-031 is offered strictly for laboratory research use. Published development of ramatercept was discontinued, and the material is not intended for therapeutic, consumer, veterinary, or diagnostic use. Buyers are responsible for compliance with their local regulations.
Can you confirm the CAS and specifications before we order?
Yes. The compound resolves to ramatercept, CAS 1169766-01-1, with a reported molecular weight near 77 kDa for the ActRIIB-Fc construct. We provide the current spec sheet and a representative COA on request so your team can verify identity and purity before purchase.
Related compounds